Raia Drogasil SA
OTC:RADLY
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Raia Drogasil SA
OTC:RADLY
|
BR |
|
S
|
Syncom Formulations (India) Ltd
NSE:SYNCOMF
|
IN |
|
M
|
Microsoft Corp
MIL:MSFT
|
US |
|
PSP Projects Ltd
NSE:PSPPROJECT
|
IN |
|
S
|
Sophia Genetics SA
NASDAQ:SOPH
|
CH |
|
Rapport Therapeutics Inc
NASDAQ:RAPP
|
US |
|
O
|
Orosur Mining Inc
XBER:UR2
|
CA |
|
S
|
SPX Technologies Inc
F:SPW0
|
US |
Wall Street
Price Targets
RADLY Price Targets Summary
Raia Drogasil SA
According to Wall Street analysts, the average 1-year price target for
RADLY
is 5.691 USD
with a low forecast of 5.104 USD and a high forecast of 6.531 USD.
Price Targets
Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.
What is RADLY's stock price target?
Price Target
5.691
USD
According to Wall Street analysts, the average 1-year price target for
RADLY
is 5.691 USD
with a low forecast of 5.104 USD and a high forecast of 6.531 USD.
What is Raia Drogasil SA's Revenue forecast?
Projected CAGR
15%
For the last 14 years the
compound annual growth rate for
Raia Drogasil SA's revenue is
22%.
The projected
CAGR
for the next 3 years is
15%.
What is Raia Drogasil SA's Operating Income forecast?
Projected CAGR
18%
For the last 14 years the
compound annual growth rate for
Raia Drogasil SA's operating income is
26%.
The projected
CAGR
for the next 3 years is
18%.
What is Raia Drogasil SA's Net Income forecast?
Projected CAGR
27%
For the last 14 years the
compound annual growth rate for
Raia Drogasil SA's net income is
23%.
The projected
CAGR
for the next 3 years is
27%.
